Objective. To assess the prevalence of dyslipidemia in 90 patients with spinal cord lesion (SCL) of duration greater than 2 years. The study was carried out from November 2007 to September 2008. Methods. Clinical history, physical examination, and lipid profiles were recorded and analyzed. Dyslipidemia was assessed using guidelines from the National Cholesterol Education Project Adult Treatment Panel III (ATP III). Results. The prevalence of dyslipidemia in at least one lipid parameter was 76.7%. The most frequent finding was low HDL-C (58.9%). Hypertriglyceridemia, hypercholesterolemia and high LDL-C were found in 28.9%, 26.7% and 21.1% of patients, respectively. The factors and age years were associated with high LDL-C ( and ). Patients who exercised less than 30 minutes per day had associated hypercholesterolemia ( ), hypertriglyceridemia ( ), and higher LDL-C ( ). Patients with BMI ？kg/m2 had associated hypercholesterolemia and high LDL-C. Age was a significant determinant of high LDL-C. BMI was the most powerful and significant determinant of hypercholesterolemia and high LDL-C. Conclusion. SCL patients should have a regular lipid checkup, especially those patients having the following risk factors: males, age years, BMI ？kg/m2 and exercise duration minutes per day. 1. Introduction There has been great improvement in therapeutic care for patients with spinal cord injury (SCI) but patients still have lower-than-normal life expectancy. It has been found that life expectancy of tetraplegia and paraplegia is less than in the normal population [1]. The major established cause of death is cardiovascular disease [2, 3]. Whiteneck [4] reported that cardiovascular disease accounted for nearly half of all deaths in persons with spinal cord injury of duration greater than 30 years. Lee et al. [5] found that the prevalence of asymptomatic coronary artery disease was 63.8% as determined by Thallium-201 myocardial perfusion single-photon emission-computed tomography (T201-SPECT). There are many important risk factors in developing cardiovascular disease such as a decrease in physical activity, obesity, metabolic syndrome, dyslipidemia, impaired glucose tolerance, and decreased cardiovascular fitness [6]. Dyslipidemia is one of the most important risk factors and can be modified for primary prevention in cardiovascular disease. In this study the prevalence of dyslipidemia was determined from ATP III guidelines which were developed from the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
References
[1]
J. D. Yeo, J. Walsh, S. Rutkowski, R. Soden, M. Craven, and J. Middleton, “Mortality following spinal cord injury,” Spinal Cord, vol. 36, no. 5, pp. 329–336, 1998.
[2]
I. B. Lidal, H. Snekkevik, G. Aamodt, N. Hjeltnes, J. K. Stanghelle, and F. Biering-S？rensen, “Mortality after spinal cord injury in Norway,” Journal of Rehabilitation Medicine, vol. 39, no. 2, pp. 145–151, 2007.
[3]
M. J. DeVivo, J. S. Krause, and D. P. Lammertse, “Recent trends in mortality and causes of death among persons with spinal cord injury,” Archives of Physical Medicine and Rehabilitation, vol. 80, no. 11, pp. 1411–1419, 1999.
[4]
G. G. Whiteneck, “Learning from empirical investigations,” in Perspectives on Aging With Spinal Cord Injury, G. G. Whiteneck, S. W. Charlifue, K. A. Gerhart, D. P. Lammertese, M. S. Manley, and R. R. Menter, Eds., vol. 32, Demos Publications, New York, NY, USA, 1992.
[5]
C. S. Lee, Y. H. Lu, S. T. Lee, C. C. Lin, and H. J. Ding, “Evaluating the prevalence of silent coronary artery disease in asymptomatic patients with spinal cord injury,” International Heart Journal, vol. 47, no. 3, pp. 325–330, 2006.
[6]
J. Myers, M. Lee, and J. Kiratli, “Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management,” American Journal of Physical Medicine and Rehabilitation, vol. 86, no. 2, pp. 142–152, 2007.
[7]
“Report of the National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. The expert panel,” Archives of Internal Medicine, vol. 148, no. 1, pp. 36–69, 1988.
[8]
S. M. Grundy and National Cholesterol Education Program, “National cholesterol education program: Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II),” Circulation, vol. 89, no. 3, pp. 1333–1443, 1994.
[9]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), “Third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report,” Circulation, vol. 106, pp. 3143–3421, 2002.
[10]
J. I. Cleeman and Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” The Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001.
[11]
S. M. Grundy, J. I. Cleeman, C. N. Bairey Merz et al., “Implications of recent clinical trials for the National cholesterol education program adult treatment panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004.
[12]
M. S. Nash and A. J. Mendez, “A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia,” Archives of Physical Medicine and Rehabilitation, vol. 88, no. 6, pp. 751–757, 2007.
[13]
W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972.
[14]
K. M. Anderson, P. W. F. Wilson, P. M. Odell, and W. B. Kannel, “An updated coronary risk profile. A statement for health professionals,” Circulation, vol. 83, no. 1, pp. 356–362, 1991.
[15]
R. B. D'Agostino Sr., S. Grundy, L. M. Sullivan, and P. Wilson, “Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation,” The Journal of the American Medical Association, vol. 286, no. 2, pp. 180–187, 2001.
[16]
W. A. Bauman, A. M. Spungen, Y. G. Zhong, J. L. Rothstein, C. Petry, and S. K. Gordon, “Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury,” Paraplegia, vol. 30, no. 10, pp. 697–703, 1992.
[17]
W. A. Bauman, R. H. Adkins, A. M. Spungen et al., “Is immobilization associated with an abnormal lipoprotein profile? Observations from a diverse cohort,” Spinal Cord, vol. 37, no. 7, pp. 485–493, 1999.
[18]
T. Ozgurtas, R. Alaca, M. Gulec, and T. Kutluay, “Do spinal cord injuries adversely affect serum lipoprotein profiles?” Military Medicine, vol. 168, no. 7, pp. 545–547, 2003.
[19]
A. J. Dallmeijer, L. H. van der Woude, G. J. van Kamp, and A. P. Hollander, “Changes in lipid, lipoprotein and apolipoprotein profiles in persons with spinal cord injuries during the first 2 years post-injury,” Spinal Cord, vol. 37, no. 2, pp. 96–102, 1999.
[20]
W. A. Bauman, R. H. Adkins, A. M. Spungen, B. J. Kemp, and R. L. Waters, “The effect of residual neurological deficit on serum lipoproteins in individuals with chronic spinal cord injury,” Spinal Cord, vol. 36, no. 1, pp. 13–17, 1998.
[21]
W. A. Bauman and A. M. Spungen, “Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging,” Metabolism, vol. 43, no. 6, pp. 749–756, 1994.
[22]
Y. G. Zhong, E. Levy, and W. A. Bauman, “The relationships among serum uric acid, plasma insulin, and serum lipoprotein levels in subjects with spinal cord injury,” Hormone and Metabolic Research, vol. 27, no. 6, pp. 283–286, 1995.
[23]
Y. Hata and K. Nakajima, “Life-style and serum lipids and lipoproteins,” Journal of atherosclerosis and thrombosis, vol. 7, no. 4, pp. 177–197, 2000.
[24]
M. Florentin, E. N. Liberopoulos, A. S. Wierzbicki, and D. P. Mikhailidis, “Multiple actions of high-density lipoprotein,” Current Opinion in Cardiology, vol. 23, no. 4, pp. 370–378, 2008.
[25]
P. Libby, “Managing the risk of atherosclerosis: the role of high-density lipoprotein,” American Journal of Cardiology, vol. 88, no. 12, pp. 3N–8N, 2001.
[26]
M. L. Kashyap, S. Tavintharan, and V. S. Kamanna, “Optimal therapy of low levels of high density lipoprotein-cholesterol,” American Journal of Cardiovascular Drugs, vol. 3, no. 1, pp. 53–65, 2003.
[27]
J. L. Durstine, P. W. Grandjean, P. G. Davis, M. A. Ferguson, N. L. Alderson, and K. D. DuBose, “Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis,” Sports Medicine, vol. 31, no. 15, pp. 1033–1062, 2001.
[28]
A. Schmid, J. Kn？ebber, S. Vogt et al., “Lipid profiles of persons with paraplegia and tetraplegia: sex differences,” Journal of Spinal Cord Medicine, vol. 31, no. 3, pp. 285–289, 2008.
[29]
A. J. Dallmeijer, M. T. E. Hopman, and L. H. V. van der Woude, “Lipid, lipoprotein, and apolipoprotein profiles in active and sedentary men with tetraplegia,” Archives of Physical Medicine and Rehabilitation, vol. 78, no. 11, pp. 1173–1176, 1997.
[30]
C. Pongchaiyakul, P. Hongsprabhas, V. Pisprasert, and C. Pongchaiyakul, “Rural-urban difference in lipid levels and prevalence of dyslipidemia: a population-based study in Khon Kaen Province, Thailand,” Journal of the Medical Association of Thailand, vol. 89, no. 11, pp. 1835–1844, 2006.
